Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study

NCT: NCT07038070 · WITHDRAWN

NCT IDNCT07038070
StatusWITHDRAWN
Start Date2025-07-01
Completion2026-05-01

Brief Summary

This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.

Frequently Asked Questions

What is Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study?

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study is a clinical trial registered under NCT07038070. Current status: WITHDRAWN.

What is the status of NCT07038070?

The current status of NCT07038070 (Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study) is: WITHDRAWN.

When did Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study start?

Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study started on 2025-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑